You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
天士力(600535.SH):子公司協議轉讓I-MAB部分非流通普通股 實現投資收益約2.2億元
格隆匯 06-11 15:44

格隆匯6月11日丨天士力(600535.SH)公佈,公司控股子公司天士力生物醫藥股份有限公司(“天士力生物”)全資子公司天士力生物科技有限公司(“天士力生物科技”)通過公開協議轉讓方式向Lake Bleu Prime Healthcare Master Fund Limited (Lake Bleu”)轉讓所持I-MAB (NASDAQIMAB)部分非流通普通股

天境生物科技有限公司(I-MAB)一家處於臨牀階段的創新生物藥公司聚焦腫瘤免疫和自身免疫疾病領域創新生物藥的早期發現,藥物開發和商業化,以填補尚未滿足的重大醫療需求。截至20201231日,總資產63.33億元,淨資產56.27億元;2020年營業收入15.43億元,淨利潤4.71億元。其主要股東:康橋資本、天士力、弘毅投資、高瓴資本、清池資本、鼎暉、厚朴

次轉讓後公司對I-MAB持股比例將由6.48%減少至5.65%按照最新人民幣兑美元匯率計算,扣除此次轉讓所對應的投資成本,實現投資收益2.2億元人民幣(具體數據以公司經審計財務數據為準)有利於提升天士力生物資產的運用效率提高投資收益

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account